InvestorsHub Logo
Post# of 253335
Next 10
Followers 839
Posts 120555
Boards Moderated 14
Alias Born 09/05/2002

Re: upndown1313 post# 35498

Sunday, 04/22/2007 12:35:26 AM

Sunday, April 22, 2007 12:35:26 AM

Post# of 253335
Roche’s R1626 HCV polymerase inhibitor has shown unacceptable neutropenia in the existing phase-2 trial (#msg-13986782). As a result, R1626 will have to be tested in a second phase-2 trial using a lower dose.

Source: Roche’s 1Q07 CC

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.